Gastric bypass keeps far more weight off than diet and drugs years later

Obesity and type 2 diabetes have reached epidemic dimensions globally, and both raise the risk of serious health outcomes while imposing a heavy daily burden on those affected. Metabolic and bariatric surgery promises sustained weight loss and improvement of comorbidities, but anyone weighing it faces two questions the short-term literature struggles to answer: how do the different operations compare with each other over the years, and how does surgery as a whole compare with lifestyle change and medication? This Cochrane review set out to answer both, focusing on outcomes at three years and beyond and ranking the options against each other.

The reviewers searched major databases through 25 June 2024 for randomised trials and cohort studies with at least three years of follow-up in adults with obesity and type 2 diabetes. Eighteen studies with 15,282 participants qualified: 13 randomised trials with 911 people and five cohort studies with 14,371. The network compared Roux-en-Y gastric bypass, sleeve gastrectomy, one-anastomosis gastric bypass, gastric banding and gastric plication against each other and against lifestyle intervention with medical treatment. Outcomes covered weight loss, waist circumference, diabetes remission, serious adverse events, all-cause mortality, blood sugar control and health-related quality of life.

Roux-en-Y gastric bypass was associated with 16.95% greater long-term weight loss than lifestyle and medical treatment, with one-anastomosis bypass and sleeve gastrectomy also ahead but on very uncertain evidence. Gastric bypass likely reduced waist circumference by 12.34 cm and may have lowered HbA1c by 1.44% versus non-surgical care. All surgical procedures may produce partial diabetes remission more often than lifestyle and medication, but that evidence is very uncertain, and the same applies to complete remission, serious adverse events and all-cause mortality. Adding the cohort studies confirmed the main findings on weight loss, partial remission, adverse events and mortality.

Surgery outperforming non-surgical care on weight is not itself new, and this review broadly confirms it while placing gastric bypass ahead of the other procedures on most measures. What it adds, and what complicates the picture, is how thin the long-term randomised evidence turns out to be: many comparisons rest on a few hundred participants, and the reviewers rate most findings uncertain or very uncertain because of bias risk and imprecision. Cohort studies were left out of the certainty ratings because their risk of bias was judged high or critical. The biggest open questions, complete diabetes remission, safety and survival, are precisely the ones patients care most about.

For a reader with obesity and type 2 diabetes who has wondered whether surgery genuinely outperforms sustained lifestyle change and medication over the long haul, this is the most rigorous answer currently available: on weight, waist size and blood sugar, it probably does, with gastric bypass leading the ranking. It is equally a reason for realism, because on complications, survival and full remission of diabetes the honest position is that nobody yet knows with confidence. This is information to bring to a conversation with a clinician, not a verdict to act on alone.